Physician profile
David Hodes
NPI 1295720647
$11,879.91
in general payments reported to CMS, 2019-2025
48 companies · $2,502 in 2025
The $2,502 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $933 · 2021: $1,584 · 2022: $1,739 · 2023: $1,761 · 2024: $2,097 · 2025: $2,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,174 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,174.17 |
| Education | $184.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,494.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,159.32 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,022.51 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $794.01 | 2019-2025 | |
| Amgen INC. | $701.75 | 2019-2025 | Tezspire, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $659.15 | 2019-2025 | Dupixent |
| Pfizer INC. | $503.36 | 2019-2025 | |
| Mylan Specialty L.P. | $396.94 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $311.21 | 2021-2025 | Glassia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $297.60 | 2019-2025 | |
| Inspire Medical Systems, INC. | $204.50 | 2024-2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $200.14 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $178.98 | 2024-2025 | |
| Insmed, INC. | $168.08 | 2021-2025 | Arikayce, Brinsupri |
| Amarin Pharma, INC. | $160.38 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $148.18 | 2019-2025 | Smartvest |
| Exact Sciences Corporation | $143.70 | 2023-2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $130.76 | 2025 | Yupelri |
| Genentech USA, INC. | $129.69 | 2019-2021 | |
| Zoll Respicardia, INC. | $87.18 | 2024 | Remede System |
| Novo Nordisk INC | $82.91 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $81.99 | 2019-2022 | |
| Verona Pharma, INC. | $79.63 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $76.71 | 2020-2022 | |
| Grifols USA, LLC | $58.27 | 2019-2020 | |
| Philips North America LLC | $57.61 | 2019 | |
| Circassia INC. | $49.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.88 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $42.60 | 2019-2021 | |
| Antares Pharma, INC. | $37.87 | 2020-2021 | |
| Optinose US, INC. | $37.71 | 2024-2025 | |
| Pulmonx Corporation | $36.31 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Bayer Healthcare Pharmaceuticals INC. | $29.35 | 2022 | |
| Medicomp INC | $27.30 | 2025 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $26.42 | 2021-2023 | Nexletol |
| Avadel Cns Pharmaceuticals, LLC | $22.56 | 2024 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $20.58 | 2025 | Uptravi, Opsumit |
| Vifor Pharma, INC. | $19.22 | 2024 | Zemaira |
| Lucid Diagnostics INC. | $19.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.22 | 2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $16.49 | 2023 | Quviviq |
| Bardy Diagnostics, INC. | $15.51 | 2022 | |
| Inogen, INC. | $15.32 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $15.31 | 2023 | Prehevbrio |
| Allergan, INC. | $15.14 | 2020 | |
| Nabriva Therapeutics, Plc | $13.34 | 2022 | |
| Abbvie INC. | $12.86 | 2022 | |
| Horizon Therapeutics Plc | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.